News

Pharmaceutical design specialist Protomed has brought together key figures from the pharma, healthcare and pharmacy arenas to debate the future of medication management (22 October). Following recent news

SuperGen and GlaxoSmithKline have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets. Under the terms of the deal, SuperGen will progress

eBioscience has acquired Bender MedSystems in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA

GeneNews has entered into an agreement allowing Eli Lilly select access to research from its osteoarthritis genomic biomarker program. Terms of the agreement were not disclosed. Heiner Dreismann,

NPS Pharmaceuticals has reported additional data from a phase 3 study supporting the efficacy of Gattex (teduglutide) in patients with parenteral nutrition (PN)-dependent short bowel syndrome (SBS). Data

Horizon Therapeutics has presented an analysis from two pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine. The

The US Patent and Trademark Office (USPTO) has notified ExonHit of its intent to issue a re-examination certificate in connection with ExonHit’s US Patent n° 6881571 directed to

Pharmalink has been granted Japanese Patent No 4326696, for its product Nefecon. It is being developed to treat IgA nephropathy. Counterparts of the patent have been issued for

Merck KGaA has announced that group total revenues rose 2.7% in the third quarter to E1,944m from E1,893m in the year-ago quarter. The group’s operating result declined by